Logo

Concert's CTP-543 Receives the US FDA's Breakthrough Therapy Designation to Treat Alopecia Areata

Share this
Concert's CTP-543 Receives the US FDA's Breakthrough Therapy Designation to Treat Alopecia Areata

Concert's CTP-543 Receives the US FDA's Breakthrough Therapy Designation to Treat Alopecia Areata

Shots:

  • The BTD is based on a P-II study assessing CTP-543 (4/8/12mg- bid) vs PBO in 149 patients with moderate-to-severe alopecia areata
  • Results: 8 & 12mg doses of CTP-543 met its 1EPs with differences in the percentage of patients achieving a ≥ 50% relative change from baseline @24wks. as measured by SALT. Therapy was well-tolerated and showed significant hair regrowth
  • CTP-543 is a JAK1 & JAK2 inhibitor and has received the US FDA’s FTD for AA. The company plans to initiate a P-III study in Q4’20

 ­ Ref: Businessswire | Image: Twitter

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions